dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Barbui, Tiziano |
dc.contributor.author | Iurlo, Alessandra |
dc.contributor.author | Masciulli, Arianna |
dc.contributor.author | Carobbio, Alessandra |
dc.contributor.author | Ghirardi, Arianna |
dc.contributor.author | Rossi, Giuseppe |
dc.contributor.author | Fox, Maria Laura |
dc.date.accessioned | 2022-04-06T07:03:34Z |
dc.date.available | 2022-04-06T07:03:34Z |
dc.date.issued | 2021-06-16 |
dc.identifier.citation | Barbui T, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Rossi G, et al. Long-term follow-up of recovered MPN patients with COVID-19. Blood Cancer J. 2021 Jun 16;11:115. |
dc.identifier.issn | 2044-5385 |
dc.identifier.uri | https://hdl.handle.net/11351/7308 |
dc.description | Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Neoplàsies mieloproliferatives cròniques |
dc.description.sponsorship | The study was supported by a research grant by the COVID “3×1 project”, BREMBO S.p.A., Bergamo, Italy (TB) and by AIRC 5×1000 call “Metastatic disease: the key unmet need in oncology” to MYNERVA project, #21267 (MYeloid NEoplasms Research Venture AIRC). A detailed description of the MYNERVA project is available at https://progettomynerva.it (AMV, PG). The study was also supported by HARMONY PLUS, which is funded through the Innovative Medicines Initiative (IMI), Europe’s largest public-private initiative aiming to speed up the development of better and safer medicines for patients. The HARMONY Alliance has received funding from IMI 2 Joint Undertaking and is listed under grant agreement No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe. |
dc.language.iso | eng |
dc.publisher | Springer Nature |
dc.relation.ispartofseries | Blood Cancer Journal;11 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | COVID-19 (Malaltia) - Tractament |
dc.subject | Trastorns mieloproliferatius - Complicacions |
dc.subject | Avaluació de resultats (Assistència sanitària) |
dc.subject.mesh | Myeloproliferative Disorders |
dc.subject.mesh | /complications |
dc.subject.mesh | Coronavirus Infections |
dc.subject.mesh | /therapy |
dc.title | Long-term follow-up of recovered MPN patients with COVID-19 |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1038/s41408-021-00509-0 |
dc.subject.decs | trastornos mieloproliferativos |
dc.subject.decs | /complicaciones |
dc.subject.decs | infecciones por Coronavirus |
dc.subject.decs | /terapia |
dc.relation.publishversion | https://doi.org/10.1038/s41408-021-00509-0 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Barbui T, Masciulli A, Carobbio A, Ghirardi A] FROM Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy. [Iurlo A] Hematology Division, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy. [Rossi G] Spedali Civili, Brescia, Italy. [Fox ML] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain |
dc.identifier.pmid | 34135309 |
dc.identifier.wos | 000664631700002 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |